Iprotiazem

This classification denotes a calcium channel blocker with the molecular formula C37H49N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3VPX99Q2D7, chemically known as ( )-(r)-2-isopropyl-4-methyl-2-(o-(4-(4-(3,4,5-trimethoxyphenethyl)-1-piperazinyl)butoxy)phenyl)-2h-1,4-benzothiazin-3(4h)-one. but generally known as iprotiazem, which bears US NIH Compound Identifier 195131. European Medicines Agency schedules Iprotiazem in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08286MIG. The term IPROTIAZEM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 1, No. 4, 1987, List 27). IPROTIAZEM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule iprotiazem under HS 29349990 and SITC 51579. As of Q4 2014, IPROTIAZEM remains the US FDA Preferred Term for this commodity. Iprotiazem bears US NLM identifiers UMLS ID C2825726 and NCI Concept Code C81678. SMILES: S1C(C(C)C)(c2c(OCCCCN3CCN(CC3)CCc3cc(OC)c(OC)c(OC)c3)cccc2)C(=O)N(c2c1cccc2)C.